BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces ...
BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has ...
In a viral TikTok, a woman alleges that BioLife, a prominent plasma donation center, wrongfully diagnosed her with Hepatitis B, leading to a lifetime ban on donating plasma. The video, posted by Kelly ...
Sarah Aebersold, the Chief Human Resources Officer of BioLife Solutions Inc. (NASDAQ:BLFS), a company with a market capitalization of $1.29 billion, reported a sale of company shares valued at ...
BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene ...
BioLife CEO Bill Jones calls for a new global health vocabulary, shifting from weight-loss language to biology-driven terms that support metabolic well-being, body positivity, and regenerative care.
BioLife Solutions, Inc. (BLFS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
BioLife Plasma, a plasma donation center, opened its 200th U.S. location and first location in Pearland on March 25. The new plasma service center located at 3020 Kirby Drive is part of the ...
GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million or 28% of revenue Raises 2025 full-year Cell Processing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback